Dianthus Therapeutics (DNTH) Net Margin (2022 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Net Margin of 41124.75% for Q3 2025, down 3769560.0% year-over-year from N/an in Q3 2024, and down 56.95% quarter-over-quarter from 26202.07% in Q2 2025.
Powered by 
Analysis
Dianthus Therapeutics (DNTH) Net Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' Net Margin history runs 4 years deep, the most recent figure standing at 41124.75% for Q3 2025.
- In Q3 2025, Net Margin fell 3769560.0% year-over-year to 41124.75%; the TTM figure through Sep 2025 stood at 9147.48% (down 504293.0% YoY), while the FY2024 annual figure was 4267.91%, up 163662.0% from the prior year.
- Net Margin for Q3 2025 stood at 41124.75%, down from 26202.07% in the prior quarter.
- The five-year high for Net Margin was 855.57% in Q4 2022, with the low at 41124.75% in Q3 2025.
- The 4-year median for Net Margin is 3429.14% (2024), against an average of 7721.04%.
- Peak annual rise in Net Margin reached 427720 bps in 2025, while the deepest fall reached 3769560 bps in 2025.
- Dianthus Therapeutics' Net Margin stood at 855.57% in 2022, then tumbled by 188 bps to 2467.61% in 2023, then climbed by 14 bps to 2121.12% in 2024, then tumbled by 1839 bps to 41124.75% in 2025.
- Business Quant data shows DNTH's Net Margin at 41124.75% in Q3 2025, 26202.07% in Q2 2025, and 3616.17% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Dianthus Therapeutics | 4.09 Bn | 3.69 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -9,250.00% |
| Jun 30, 2025 | -16,333.68% |
| Mar 31, 2025 | -2,838.61% |
| Dec 31, 2024 | -2,106.03% |
| Sep 30, 2024 | -1,171.96% |
| Jun 30, 2024 | -1,192.38% |
| Mar 31, 2024 | -2,050.11% |
| Dec 31, 2023 | -2,300.22% |
| Sep 30, 2023 | -1,594.37% |
| Jun 30, 2023 | -1,108.90% |
| Mar 31, 2023 | -1,415.40% |
| Dec 31, 2022 | -855.57% |
| Sep 30, 2022 | -668.20% |